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Background: The common cold is the most widespread viral infection in humans. Iota-carrageenan has
previously shown antiviral effectiveness against cold viruses in clinical trials. This study investigated the efficacy of a
carrageenan-containing nasal spray on the duration of the common cold and nasal fluid viral load in adult patients.
Methods: In a randomized, double-blind, placebo-controlled trial, 211 patients suffering from early symptoms of
the common cold were treated for seven days. Application was performed three times daily with either a
carrageenan-supplemented nasal spray or saline solution as placebo with an overall observation period of 21 days.
The primary endpoint was the duration of disease defined as the time until the last day with symptoms followed
by all other days in the study period without symptoms. During the study, but prior unblinding, the definition of
disease duration was adapted from the original protocol that defines disease duration as the time period of
symptoms followed by 48 hours without symptoms.
Results: In patients showing a laboratory-confirmed cold virus infection and adherence to the protocol, alleviation
of symptoms was 2.1 days faster in the carrageenan group in comparison to placebo (p = 0.037). The primary
endpoint that had been prespecified but was changed before unblinding was not met. Viral titers in nasal fluids
showed a significantly greater decrease in carrageenan patients in the intention-to-treat population (p = 0.024) and
in the per protocol population (p = 0.018) between days 1 and 3/4.
Conclusions: In adults with common cold virus infections, direct local administration of carrageenan with nasal
sprays reduced the duration of cold symptoms. A significant reduction of viral load in the nasal wash fluids of
patients confirmed similar findings from earlier trials in children and adults.
Trial registration: Current Controlled Trials ISRCTN80148028
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Acute viral respiratory tract infection (ARTI), also known
as the common cold, is the most prevalent disease in
humans. In the USA alone, non-influenza colds annually
account for more than 20 million doctor visits and 40
million lost school and work days. With a total economic
impact of approximately $40 billion, ARTI is among the
ten most expensive illnesses in society [1].
In the majority of cases, common colds are caused
by respiratory viruses such as rhinovirus, coronavirus,* Correspondence: christian.a.mueller@meduniwien.ac.at
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reproduction in any medium, provided the orparainfluenza, influenza, respiratory syncytial virus, adeno-
virus, enterovirus, or metapneumovirus [2-7].
The number of etiological agents and antigenic vari-
ability has limited the possibility of creating an effective
vaccine against the common cold. Numerous attempts
to find effective prophylactic or therapeutic treatments
including pharmaceutical [8] and herbal [9,10] products,
vitamins [11-14], zinc [15] and others have provided
controversial results and are not considered effective
when systematically reviewed [16-21].
Presently, therapy for the common cold mainly includes
general care and treatment of symptoms. While these
measures reduce symptoms, therapeutic interventionsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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viral load or the duration or severity of common colds [22].
The concept of using sulphated polysaccharides as
antiviral agents was introduced more than 25 years ago
[23]. Due to the high molecular weight of polymers,
parenteral administration is not feasible. For the treatment
of sexually transmitted diseases, research has focused
on topical microbicide development although not enough
evidence has accumulated to recommend these agents at
present. However, these polysaccharides have been tested
to prevent sexually transmitted viral infections as a com-
ponent of spermicides [24,25].
Recently it was shown that iota-carrageenan, a sulphated
polysaccharide found in some species of red seaweed, is a
potent antiviral agent against respiratory viruses in cell
culture and animal models [26,27]. Laboratory data show
that the carrageenan-polymer binds directly to the virus
but not to cells trapping the particle and preventing cell
attachment. Thus, carrageenan interferes with the virus
life cycle at a very early stage due to a physical mechanism
of action. Studies in vitro and in vivo have shown the
effectiveness of carrageenan against several viruses such as
hRV [27], influenza A [26] and RSV. Tests in vitro have
shown that carrageenan does not penetrate the mucosa.
Therefore, pharmacological, immunological or metabolic
activities of carrageenan are not to be expected.
In addition to preclinical studies, symptomatic benefit
and antiviral efficacy of a nasal spray containing carra-
geenan has been shown in two randomized clinical trials
in adult [28] and pediatric patients with the common
cold [29]. This study was designed to investigate the
efficacy of a carrageenan-containing nasal spray on the
duration of the common cold and the viral load in nasal
fluid in adult patients.
Methods
Study subjects
All patients were recruited at the Department of
Otorhinolaryngology of the Vienna General Hospital,
Austria between January, 2010 and April, 2011. Eligible
patients were adults (18 years and older) with early symp-
toms of the common cold (onset less than 48 hours before
inclusion) of mild to moderate intensity (Total Symptoms
Score [TSS], of 2 to 9).
The intensity of common cold symptoms was assessed
according to a published scoring system [30]. Patients
scored eight main symptoms (headache, muscle ache,
chilliness, sore throat, blocked nose, runny nose, cough-
ing and sneezing) using a four point scale as follows:
0 (symptom absent) and 1, 2 and 3 representing mild,
moderate and severe intensity, respectively. TSS was cal-
culated by investigators as the sum of individual scores.
Main exclusion criteria were known hypersensitivity or
allergy to any component of the test product, concomitantdisease or infection that could interfere with participation
in the study, other reasons for nasal obstruction and
other past or present conditions and treatments that
could influence symptom scores. Specifically, during the
treatment period (days 1–7), use of any other nasal spray,
nonsteroidal anti-inflammatory drugs, antihistamines,
decongestants, corticosteroids, antivirals, antitussives, herbal
combinations for common colds and supplements contain-
ing ≥10 mg zinc or ≥100 mg vitamin C were prohibited.
The study was performed in compliance with the
ICH E6 Note for Guidance on Good Clinical Practices
(CPMP/ ICH/ 135/ 95/ 5) and the principles of the
Declaration of Helsinki. The Ethics Committee of the par-
ticipating site approved the protocol and all amendments.
Written informed consent was obtained from each partici-
pant before enrolment into the study. Participants were
compensated for expenses associated with participation.
Study design
This was a single-center, double-blind, parallel-group,
placebo-controlled, randomized (1:1) clinical trial to show
differences between carrageenan-containing nasal spray
over placebo in adult patients with early symptoms of
the common cold.
The objective of this trial was to obtain information
on the efficacy of carrageenan-containing nasal spray
(Coldamaris prophylactic) in adult patients with early
symptoms of the common cold. The aim was to show
at least 2 days reduction in the duration of disease with a
standard deviation (SD) of 4.9. This resulted in a sample
size of 96 per group. With a maximal drop-out rate ex-
pected of 25%, the sample size was set at 125 patients
per group. Type-I error probability was set to a two-sided
alpha of 0.05. Power was set to 80 percent.
Study procedures
All patients were randomly assigned to receive either
Coldamaris prophylactic nasal spray containing carra-
geenan (0.12%) or saline solution (sodium chloride 9.0 g/l)
nasal spray, which served as a placebo. Nasal spray was
administered three times daily into each nostril for 7 days.
Coldamaris prophylactic nasal spray is a registered medical
device marketed in Austria and manufactured by MoNo
chem GmbH, Austria.
Each subject was randomised to one of the two groups
according to a randomization schedule using random
permuted blocks (block size of 4). The randomization list
was prepared by a third party and was unblinded after trial
review and data base lock.
Each nasal spray had a three-digit code. The sprays
were assigned by investigators consecutively starting with
the lowest treatment number available. Both investigators
and patients were blinded to study treatment. Carrageenan
and placebo nasal sprays were identical in shape, size and
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and free of particulates.
For all enrolled subjects, medical histories were evaluated
at baseline. Clinical assessments including ear, nose and
throat examination were performed and nasal wash fluid
for laboratory testing (viral assessment) was obtained.
ENT examinations and nasal wash fluid collection were
repeated on days 3/4 (visit 2) and 10/11 (visit 3). During
visits, safety evaluation was also conducted. On the last visit
(days 22–28), in addition to final safety assessments,
all subjects were questioned regarding their opinion as
to the acceptability of the study treatment.
During days 1 to 9, patients had to record whether they
used the nasal spray as instructed, the presence of any
additional symptoms, the use of any additional treat-
ments and scores for the 8 main common cold symptoms
described above. This diary had to be returned to the study
site at visit 3.
From days 10 to 21, patients kept diaries on a daily basis
and recorded common cold symptoms experienced and
the product and dosage of any other treatments taken.
Compliance with study treatment was assessed by
measuring the weight of the dispensed nasal spray on
the days of issuance and return. A difference of less
than 4.0 g was assessed as consumption less than 80%
of study protocol and such patients were subsequently
excluded from PP analysis.
Viral status assessment
Nasal wash fluid samples were obtained for virological
analysis at baseline (day 1), at visit 2 (study days 3/4) and
visit 3 (study days 10/11) using the following procedure.
Approximately 2.5 ml of 0.9% saline solution were instilled
into each nostril and kept in the nose for 10–30 seconds.
Patients were then required to lean the head forward allow-
ing saline to drip out of the nose into a collection cup. After
collection, mucus was removed and the sample divided into
3 cryovials, labelled and stored at −80°C until assessment.
The presence and the amount of viral RNA in nasal wash
fluid samples was identified using a real-time, quantitative
RT-PCR assay as described previously [29]. Analyses for the
respiratory viruses rhinovirus, coronavirus type OC43, cor-
onavirus type 229E, influenza virus type A and B, human
metapneumovirus, respiratory syncytial virus and parainflu-
enza types 1, 2 and 3 were performed.
A patient was considered to be virus-positive when
at least one nasal wash fluid sample was tested positive
for one virus.
Endpoints
The primary efficacy variable was the duration of disease
defined as the time until the last day with symptoms
followed by all other days in the study period without
symptoms.The main secondary efficacy variables were the presence
of cold viruses in nasal fluid samples, severity of common
cold symptoms on separate study days, number of days
without symptoms during the observation period, use of
co-medication additional to the study treatment between
days 8–21 (after finishing treatment with the carrageenan
nasal spray) and the number of cleared or newly acquired
viral infections during the observation period.
During the course of the study, but prior to unblinding
the data and performing analysis, the following efficacy
outcomes were adapted based on results obtained in a
previous common cold trial. The primary efficacy par-
ameter was changed from “the time period between
first and last day with symptoms followed by 48 hours
without symptoms” to “the time period between first
and last day with symptoms, followed by all other days
without symptoms” – a definition that was used in another
study of carrageenan in a pediatric population [29]. Due
to the physical mechanism of action of the tested polymer,
only patients with a cold virus in the nasal cavity are
likely to benefit from local antiviral treatment with
iota-carrageenan. Hence, analysis of effectiveness was
carried out for patients with laboratory confirmed cold
virus infection (Figure 1). Therefore, the intention-to-
treat virus positive population (ITT-VP) as well as the
per protocol virus positive population (PP-VP) were
assessed. For analysis of safety data all patients who re-
ceived a study medication were included (ITT). The
protocols, all amendments including those to the pri-
mary endpoint and the assessment of the virus positive
population were approved by the local ethics committee
prior unblinding of the study.
Statistical analysis
The primary end point was analysed using the log rank test
and the Mantel-Haenzel test. All data sets were checked
for normal distribution by the Kolmogorov-Smirnov-Test
prior to analysis. Binary or categorical data (e.g. presence
or absence of viruses, number of patients with adverse
events [AE]) were analysed by the Chi-square test.
Viral titer in nasal wash fluids as well as changes in titers
between visits were analysed using the median test due to
high variability. In the dataset for this analysis, all viruses
detected were included and each virus was accounted for
individually. Since some patients had more than one virus,
the number of viral events was higher than the number of
infected patients.
Experience from previous trials suggested that TSS data
might not be normally distributed and lopsided. This was
confirmed for the actual study with a Kolmogorov-Smirnov
test and a test for lopsided distribution of data. Hence
analysis of TSS with standard conventional methods was
not applicable. Prior to unblinding, it was decided to apply
the analysis of ReWuMoD (regression with unknown model
Figure 1 COP 03/09 trial, patient flow chart.
Ludwig et al. Respiratory Research 2013, 14:124 Page 4 of 11
http://respiratory-research.com/content/14/1/124
Ludwig et al. Respiratory Research 2013, 14:124 Page 5 of 11
http://respiratory-research.com/content/14/1/124domain, Additional file 1: Figure S1) technique instead
of conventional statistical methods. The principles of
this technique have been described in detail previously
[31]. Briefly, this model transformed 10 TSS values
(baseline and days 1–9) into a two line regression model
for each individual patient. The average parameters of these
two lines allowed the comparison of the course of the dis-
ease between the treatment groups irrespective of absolute
TSS values.
ReWuMoD analysis yields a reduction from ten individual
data points (TSS values) to five relevant parameters. Inter-
cept and slope of the first straight line (with the parameters
a1 and b1; representing the course of the early phase of the
disease), the estimated/calculated break point (BP) between
the two lines (representing the time point of the change in
the course of the disease) and the parameters of the second
line (abbreviated as a2 and b2; representing the course
of the later phase of the disease).
It was further reasoned that the ReWuMoD model is
less sensitive to absolute score values allowing the
evaluation of different courses of disease independent
of absolute values.
Safety
All findings after the screening visit were documented as
AEs except for any symptoms attributed to common cold
(sneezing, runny nose, nasal obstruction, sore throat,
cough, headache, fatigue and chilliness) as defined in the
protocol. Nevertheless, if such symptoms were of marked
intensity or deemed to be not related to the study disease,
these were recorded as AEs.
Results
Patients
Altogether, 211 patients with suspected common cold
were randomized with 203 completing treatment in the
ITT population. Reasons for patient exclusion were lost to
follow-up (5 patients) and exclusion according to protocol
(3 patients). None of the patients discontinued treatment
due to adverse events (Figure 1).
The PP population consisted of 178 patients. Main
reasons for exclusion were the use of prohibited medica-
tions (n = 14) and non-compliance (n = 10). Additionally,
one patient was enrolled with violation of inclusion/
exclusion criteria (chronic obstructive pulmonary disease
as concomitant disease).
The virus positive populations consisted of 118 patients
in the ITT-VP and 103 patients in PP-VP groups (Figure 1).
The ITT population comprised 110 females (59 placebo
and 51 carrageenan) and 93 males (42 placebo and 51
carrageenan). The mean age was 33.3 years in the placebo
and 33.7 years in the carrageenan group.
There were no statistically significant differences in
demographic variables, smoking status and intensity ofsymptoms between treatment groups in the ITT/ITT-VP
(Table 1) or PP/PP-VP (data not shown) populations.
Virus identification
In total, 118/203 (58.1%) patients in the ITT population
had a laboratory confirmed infection with at least one com-
mon cold virus, with no significant difference in virus distri-
bution between the groups. Total numbers of virus-positive
patients per treatment group as well as numbers of patients
infected with specific viruses are shown in Table 2. Influ-
enza virus B, and parainfluenza virus types 1 and 2 were
not detected in any of patients. 15% of patients tested posi-
tive for more than one virus in the nasal fluid.
Primary endpoint: duration of disease
In patients with a laboratory confirmed cold virus infec-
tion, analysis with a log-rank test showed faster recovery
in iota-carrageenan treated patients compared to placebo
in the PP-VP population with an estimated duration
of disease of 11.6 days (95% confidence interval [CI];
10.4-12.9 days) in the carrageenan group compared to
13.7 days (95% CI; 12.2-15.1 days) in the placebo group
(log-rank test, p = 0.037, Figure 2B).
The relative risk for iota-carrageenan treated PP-VP
patients to reduce the symptoms for 1 day was 1.24
(95% CI; 0.88-1.73). The absolute risk reduction (ARR)
was −0.13 (95% CI; -0.32-0.08) and the number needed
to treat (NNT) was 7.8 (95% CI; 3.1-infinite).
A similar trend was observed in the ITT-VP population,
however, the difference was not statistically significant
(log-rank test, p = 0.077, Figure 2A). The applied log rank
test is more sensitive when the ratio of hazards is higher
at early survival times, which is clearly not the case in this
study. Further analysis with the Mantel-Haenszel test
revealed slightly different p-values but did not change
the overall result (ITT-VP: p = 0.051, PP-VP p = 0.020).
The relative risk for iota-carrageenan treated ITT-VP pa-
tients to reduce the symptoms for 1 day was 1.09 (95% CI;
0.79-1.49). The ARR was −0.051 (95% CI; -0.24-0.14)
and the number needed to treat NNT was 19.6 (95% CI;
4.1-infinite).
In the ITT population (N = 203) no statistical significance
for the duration of disease was observed.
Symptoms scores
Analysis of TSS using ReWuMoD in virus-positive pop-
ulations (ITT-VP and PP-VP) did not show statistically
significant differences between groups during the early
phase of the disease. However, in the ITT-VP population
the break point was achieved in the carrageenan group
0.5 days earlier (mean 3.4 days in the carrageenan arm
compared to a mean 3.9 days in the placebo arm, p = 0.025,
possibly representing an earlier start of the recovery phase),
followed by a significant faster reduction of symptom
Table 1 Demographic and baseline characteristics, ITT and ITT-VP population
ITT ITT-VP
Carrageenan Placebo Carrageenan Placebo
n % n % p value n % n % p value
Gender
Male 51 50.0% 42 41.6% 29 49.2% 24 40.7%
Female 51 50.0% 59 58.4% 0.23* 30 50.8% 35 59.3% 0.36*
Mean SD Mean SD Mean SD Mean SD
Age, years 33.7 12.9 33.3 12.9 0.84** 31.6 12.0 32.6 12.9 0.65**
Weight, kg 74.0 15.4 73.8 15.7 0.95** 71.5 13.1 70.1 13.8 0.56**
Height, cm 174.0 10.4 173.2 9.4 0.55** 174.3 10.1 172.8 9.9 0.86**
n % n % n % n %
Smoking status
Active smoker 36 35.3% 32 31.7% 0.59* 24 40.7% 17 28.8% 0.18*
Passive smoker 25 24.5% 22 21.8% 0.65* 17 28.8% 13 22.0% 0.40*
Active OR passive smoker 44 43.1% 40 39.6% 0.61* 30 50.8% 21 35.6% 0.09*
Mean SD Mean SD Mean SD Mean SD
Baseline TSS 6.3 2.0 6.4 1.9 0.56** 6.3 2.0 6.4 1.7 0.77**
*Chi-square test.
**t-test.
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0.56 points/day in the carrageenan group compared to
a mean 0.24 points/day in the placebo group, p = 0.029,
Figure 3A) in the second phase of the disease. Similar
results were also observed in PP-VP patients. The
break point was observed earlier in the carrageenan
group (mean 3.4 days in carrageenan compared to a
mean of 3.9 days in placebo, [p = 0.064]), and this was
followed by a faster decrease in TSS during the second
phase of the disease. The mean TSS decreased 0.55
points/day in the carrageenan group compared to 0.23
points/day in the placebo group (p = 0.048, Figure 3B).
In the ITT (N = 203) no difference for the breakpoint was
observed. In the second phase of the disease TSS decreased
0.58 points/day in the carrageenan group compared to 0.34
points/day in the placebo group (p = 0.045).
A posthoc analysis of symptom data revealed that in
the ITT-VP population, 39 patients (33%) had re-appearing
symptoms (25 placebo patients and 14 carrageenan patients).
This difference between the groups was significant with
a p-value of 0.031.Table 2 Number of virus-positive patients and virus distributi
n VP patients* RSV Corona 229E Coro
ITT 118/203 4 32
V 59/102 3 16
P 59/101 1 16
*Some patients had more than one virus.
hMPV = Human metapneumovirus; hRV = Human rhinovirus; ITT = Intention to treat
VP = Virus-positive patients.Use of additional treatments
Overall, the number of patients taking medications for
common cold symptoms was low (less than 17% in total)
with 15 patients in the carrageenan group and 19 patients
in the placebo group taking additional medications (ITT)
during the study period. In the PP population, 6 patients
in the carrageenan group compared to 14 patients in
the placebo group consumed additional medication. The
difference between the groups represents a trend but was
not statistically significant (p = 0.065).
Viral load in nasal fluid
In the nasal fluid of both carrageenan and placebo pa-
tients, viral titers decreased from visit 1 to visit 2.
However, carrageenan treated patients showed a sig-
nificantly greater decrease in viral titer between visit 1
and visit 2 (Figure 4). In the ITT-VP population, the
median decrease of the log10 viral titer was 2.15 in the
carrageenan group compared to 1.38 in the placebo
group (p = 0.024, Figure 4A). In the PP-VP population,
these figures were 2.19 and 1.37 for the carrageenanon between treatment groups*
na OC43 hMPV hRV Influenza A PIV3
21 5 60 13 1
13 2 27 7 0
8 3 33 6 1
















































































Figure 2 Alleviation of symptoms in patients infected with a
cold virus treated either with intranasal Carrageenan or placebo.
Alleviation was defined as the time until complete absence of cold
symptoms followed by all other days in the study period without
cold symptoms. Figure 2A shows the ITT-VP population p = 0.077

















































Figure 3 Mean daily rate of TSS reduction in the second phase
of the cold. The mean daily rate of TSS reduction was calculated
from the variable a2 that was determined by ReWuMod analysis and
is shown for the ITT-VP (3A), p = 0.029 and PP-VP populations (3B)
p = 0.048. Details describing the ReWuMod analysis are shown in
supplementary Figure 1.
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Median titers at visit 3 (day 10) were 0 for all patient
groups and no further analysis was performed.
Safety
Overall, the study treatment was well tolerated and no
statistically significant differences were found between the
study groups regarding the total number or distribution of
AEs. In total, 43 AEs (related or not related) were reported,
involving 38 subjects (19 subjects in each treatment group)
in the trial. There was no significant difference in the
frequency of AEs between treatment groups, with the
majority of AEs observed only once or twice per SOC
(System Organ Class) category (corresponding to a
frequency of 0.94% - 1.92%).
Only one AE in the placebo group (the feeling of
burning in the nose) was considered to be related to
study treatment by the investigator. The vast majority
of AEs (41 of 43) were of mild intensity. One AE in
the carrageenan group (cycling accident with cerebralcommotion and subarachnoidal hemorrhage) was of
moderate intensity and one AE in the placebo group
(gastric hypermotility) was rated as severe.
In this study, 3 severe AEs in 2 patients (not related and
resolved by the end of the study) were reported in the
carrageenan group. None of the patients discontinued
treatment or participation in the trial due to an AE.
Discussion
This double blind placebo controlled trial evaluated the
effectiveness of a carrageenan nasal spray for the treatment
of adult patients with common cold symptoms. This study
confirms the results of earlier studies in adults and children.
For patients compliant to the protocol and positive for
a cold virus infection, a reduction of disease duration



































Figure 4 Differences in viral load between days 1 and 3/4. The
median log10 difference of the viral load between days 1 and days 3
or 4 determined with quantitative real time PCR for a set of
respiratory viruses as described in the materials and methods is
shown. The titers were compared by applying a Median-test.
A: ITT-VP p = 0.024; B: PP-VP: p = 0.018. The black bar shows
Iota-Carrageenan and the grey bar shows placebo.
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a significant clinical benefit. A pronounced trend was also
observed in the ITT-VP population although differences
did not reach the level of statistical significance. The main
difference between the ITT-VP and PP-VP populations
is the use of concomitant medication during the study.
Patients were excluded from the PP analysis due to insuffi-
cient use of study medication when a reduction of dosage
of more than 20% corresponding to 1.5 days of treatment
was documented. Thus it can be concluded that tested dos-
age of 3 times per day is necessary and fewer applications
may lead to a reduced clinical benefit.
As mentioned in the materials and methods section
the primary endpoint was changed during the course of
the study, prior unblinding and with approval of the ethics
committee based on results of an earlier study in children.
Analysis of the duration of disease according to the
endpoint “time period between first and last day withsymptoms followed by 48 hours without symptoms”
did not result in significant difference in any analysed
population neither in the adults or children. Hence, it
can be concluded that a part of the positive effect of
iota-carrageenan treatment is based on the ability to
prevent the reappearance of symptoms when there is a
symptom free period longer than 48 hours.
The results reported are limited to patients tested positive
with real-time PCR, which is 58% of the study population.
Analysis of the primary endpoint for the complete study
population (ITT, N = 203) did not reveal a significant differ-
ence between the iota-carrageenan and the placebo group.
However, analysis of TSS using ReWuMoD revealed a sig-
nificant faster reduction of symptoms in the second phase
of the disease. Similar to the ITT-VP group the reduction
of symptoms in the iota-carrageenan group was approxi-
mately doubled when compared with the placebo group.
This result indicates that independent of the actual cause
of symptoms, iota-carrageenan treatment results in a faster
reduction of symptom severity.
Due to the physical mechanism of action of carrageenan,
it is unlikely that patients with cold symptoms not caused
by a virus would have an added benefit in comparison to
placebo treatment with a saline nasal solution. Treatment
of common colds with saline nasal irrigation has been
discussed to have a clinical benefit and has been described
to be associated with less time off work [32]. Conse-
quently, the current study is limited by the fact that the
placebo nasal spray containing a saline nasal solution most
likely has caused a clinical benefit as well. This could ex-
plain why no significant effect on the primary endpoint in
the ITT population was observed in this trial in contrast
to the virus positive population that comprised 58% virus
positive patients.
A recent study in children with a similar design revealed
a significant reduction of time to disease clearance of
1.8 days in the ITT population comparable to this study
[29]. In that children trial around 90% of the children were
tested virus-positive and hence there was negligible differ-
ence between the ITTand the ITT-VP population, although
also in this study the ITT-VP population experienced a
stronger effect of treatment with carrageenan. It can be
assumed that both, adults and children infected with
common cold viruses will benefit from local application
of carrageenan in a similar way. In adults, the effect on
disease duration might be masked by patients with cold
symptoms not caused by viral infections. However, the
faster rate of symptom reduction in all iota-carrageenan
treated adults suggests that all patients with cold symptoms
will have an added benefit when compared with a standard
saline nasal spray that served as a placebo in the trial.
Analysis of TSS showed faster symptom improvement
in carrageenan treated patients during the second phase
of disease with statistically significant differences in the
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(representing changes in course of disease and start of
recovery) was earlier in the ITT-VP and PP-VP in carra-
geenan patients. The applied ReWuMod method allows
the evaluation of different courses of disease independent
of absolute values. This was of particular interest as abso-
lute values depend on different pathogens and subjective
patient assessment. No significant difference in TSS
between carrageenan and placebo groups was observed
in the first 3 days of the study. However, carrageenan
treated patients experienced a significantly earlier improve-
ment in disease symptoms. Furthermore, the rate of symp-
tom reduction per day was approximately doubled. It can
therefore be concluded that the significant reduction in
time to disease clearance was achieved by a faster decrease
of symptoms visible on day 4 after inclusion.
The results are in line with data from a trial conducted
in adults that showed a significant benefit on TSS in a
relatively small group of patients [28]. The trial conducted
by Eccles et al. showed that within the first two days after
inclusion, patients did not report an improvement in
symptom scores. However, starting on day 3, carrageenan
treated patients reported a greater reduction in TSS than
placebo patients, resulting in a significant clinical benefit
and a significant reduction in TSS on day 3. The clinical
relevance of this finding is supported by the fact that
symptom scores on day 3 of carrageenan treated patients
were at the same levels as placebo treated patients on day
5, indicating a reduction in time to symptom alleviation
of 2 days. This compares well with the 2.1 day reduction
obtained in this trial.
Similar to all studies with the natural common cold, this
trial is limited by an uncertainty over the actual dates and
times of disease onset. There is a potential for inclusion of
patients at later stages of disease which could be a source
of bias diminishing treatment efficacy in natural settings.
Comparing results from studies of natural and experimen-
tal colds suggested that a substantial proportion of pa-
tients with natural colds suffered from symptoms up to
1 day longer than they reported [33]. Furthermore, in one
study analysis of patient records revealed that up to 35%
of patients with a natural cold, who reported being sick
for up to 48 hours (inclusion criteria), were in fact ill for
3 days and more [34]. As in any antimicrobial or antiviral
intervention, an early start of treatment with carrageenan
is likely to provide the best benefit for patients.
The rate of exposure of cigarette smoke in this trial was
high (Table 1) Emerging evidence suggests that cigarette
smoke affects viral and bacterial binding to epithelial
cells [35,36]. A post hoc analysis was conducted to re-
veal whether iota-carrageenan treatment is beneficial
for patients exposed to cigarette smoke. Iota-carrageenan
treated patients in the ITT-VP smoke exposed population
(includes smokers and smoking exposed) showed anestimated duration of disease of 10.0 days (95% confidence
interval [CI]; 8.1-12.0 days) in the carrageenan group com-
pared to 13.6 days (95% CI; 10.9-16.3 days) in the placebo
group (log-rank test, p = 0.031). When compared with the
general population it is interesting that smoke exposed
iota-carrageenan treated patients had a shorter duration of
disease while there was no difference in the placebo group.
The trial was neither designed nor powered to demonstrate
the effect in this particular subgroup. Hence this encour-
aging results need to be viewed with caution.
A secondary objective of the study was the determin-
ation of viral pathogens and intranasal viral loads. Analysis
of nasal fluid samples yielded seven different respiratory
viruses (Table 2). As expected in common cold patients,
more than 80% of virus positive patients suffered from a
rhinovirus or corona virus infection. Viral titers in both
carrageenan and placebo treated groups decreased
from baseline to the second visit on day 3/4. This re-
sult is expected in the natural course of the common
cold. However, the magnitude of reduction was greater
in patients receiving the carrageenan nasal spray and
was statistically significant in the ITT and the PP popu-
lation. The data correspond to results from two earlier
clinical trials in adults and children that both revealed
a significant reduction of viral load in the nasal secre-
tion of carrageenan patients [28,29].
In this trial intranasal treatment with the carrageenan
nasal spray was safe. No drug related serious adverse
events were detected. This is most likely attributed to the
physical mechanism of action and the fact that carrageenan
is not capable of cell invasion. Due to the presumably very
low rate of serious adverse events the study was insuffi-
ciently powered to detect them.
Conclusions
The use of carrageenan nasal spray was associated with
a significant reduction of viral load in nasal fluids. Common
cold patients with laboratory confirmed cold virus and
compliant with study treatment showed shorter duration of
disease and faster reduction of common cold symptoms
when treated with carrageenan. Furthermore, the use of
carrageenan nasal spray was safe and well tolerated. Appro-
priate dosage seems to be essential and early intervention
is suggested to result in significant clinical effectiveness.
Therefore, iota-carrageenan may be a good alternative
treatment for viral infections of the upper respiratory tract
known as the common cold.
Additional file
Additional file 1: Figure S1. Description of ReWuMod analysis.
a1 = start point of the first regression line (y-axis). b1 = slope of line 1,
representing the rate of improvement during the initial phase of the
disease. BP = break point between line 1 and 2 in days (x-axis),
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http://respiratory-research.com/content/14/1/124representing the time point of the change in the course of the disease.
a2 = start point of the second regression line (y-axis). b2 = slope of line 2,
representing the rate of improvement during the later phase of the disease.
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